The use of low-molecular-weight heparins in pregnancy – how safe are they?

@article{Deruelle2007TheUO,
  title={The use of low-molecular-weight heparins in pregnancy – how safe are they?},
  author={Philippe Deruelle and Capucine Coulon},
  journal={Current Opinion in Obstetrics and Gynecology},
  year={2007},
  volume={19},
  pages={573–577}
}
Purpose of review Low-molecular-weight heparins are in widespread use during pregnancy. As with every treatment in pregnant patients, concerns have been raised about the safety of Low-molecular-weight heparins. The purpose of the present article is to review recent advances, published during the past year, that have studied the maternal, fetal, and neonatal safety of Low-molecular-weight heparins in pregnant women. Recent findings Low-molecular-weight heparins do not increase the risk of… Expand
Fetal and neonatal effects of anticoagulants used in pregnancy: a review.
There are several relative (promising regarding a reduction in placenta-mediated complications such as preeclampsia) and absolute (e.g. a recurrent or recent thromboembolic event, mechanical heartExpand
Outcomes in women receiving low-molecular-weight heparin during pregnancy
To assess the rate and type of maternal and infant complications among pregnant women receiving low-molecular-weight heparin (LMWH). Retrospective study of pregnant women on LMWH referred to twoExpand
Evaluation of the Efficacy of Aspirin and Low Molecular Weight Heparin in Patients with Unexplained Recurrent Spontaneous Abortions
TLDR
Thromboprophylaxis with ASA and LMWH seems to be safe and effective in patients with URSA and there were no differences in obstetrical complications, prenatal and neonatal complications between the two groups. Expand
Efficacy and safety of two doses of low molecular weight heparin (enoxaparin) in pregnant women with a history of recurrent abortion secondary to antiphospholipid syndrome
TLDR
There were no significant differences between two doses of low molecular weight heparin (enoxaparin) in pregnant women with a history of recurrent abortion secondary to antiphospholipid syndrome or puerperium. Expand
HIGH PRESCRIPTION OF LOW MOLECULAR WEIGHT HEPARINS DURING PREGNANCY IN A HOSPITAL IN TETOVO, THE REPUBLIC OF MACEDONIA
TLDR
There is an urgent need to improve the prescription of anticoagulants in the Department of Gynecology and Obstetrics, Clinical Hospital of Tetova, Republic of Macedonia, for venous thromboembolism treatment and prophylaxis during the period of pregnancy. Expand
Low-Molecular-Weight Heparin for the Treatment of Unexplained Recurrent Miscarriage With Negative Antiphospholipid Antibodies: A Randomized Controlled Trial
TLDR
Early start of low-molecular-weight heparin decreases the incidence of miscarriage in the first 20 weeks of pregnancy in women with unexplained RM negative for APAs. Expand
Treatment of venous thromboembolism during pregnancy.
TLDR
It is evident that LMWH is the preferred option for treatment of VTE during pregnancy, because it offers better bioavailability, fewer injections, superior safety regarding HIT and osteoporosis. Expand
Birthweight in pregnant women with protein S deficiency treated with low-molecular-weight heparin: a retrospective cohort study
TLDR
In women with PS deficiency treated with LMWH, the risk of small-for-gestational-age (SGA) and intrauterine growth retardation (IUGR) in pregnant women with protein S (PS) deficiency is similar to the one found in healthy pregnant women. Expand
Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
TLDR
Heptest-STAT is a new clotting assay for monitoring of LMWHs, which has been optimised for use in near-patient laboratory instrumentation and shows a similar dose-response in Heptest compared to the chromogenic anti-factor Xa assay. Expand
Anticoagulants, thrombocyte aggregation inhibitors, fibrinolytics and volume replacement agents
TLDR
The aim of this chapter is to provide the clinician with an overview of the known teratogenic effects of currently used antithrombotic agents as well as recommendations for their appropriate use during pregnancy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Low molecular weight heparin in pregnancy: current issues
TLDR
There is poor consensus and wide disparity of views among experts with regard to the appropriate dose for the varying indications, the duration of treatment, and whether and how LMWH should be monitored because of the lack of an evidence base. Expand
Use of low molecular weight heparin in pregnancy.
TLDR
It is concluded that LMW heparin does not cross the placental barrier, and in addition offers satisfactory antithrombotic protection for both maternal and placental circulation. Expand
Safety of low-molecular-weight heparin in pregnancy: a systematic review.
TLDR
It is concluded that low-molecular-weight heparins appear to be a safe alternative to unfractionated heparin as an anticoagulant during pregnancy. Expand
Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias.
TLDR
This uncontrolled trial suggests that patients with obstetric complications and an inherited thrombophilia may benefit from treatment with combined LMW heparin and aspirin in subsequent pregnancies, but this needs to be verified by controlled trials before considering clinical application. Expand
Use of low-molecular-weight heparin from the first trimester of pregnancy: a retrospective study of 111 consecutive pregnancies.
TLDR
The use of low-molecular-weight heparin (LMWH) for patients requiring anticoagulant treatment from the first trimester appears safe for mother and fetus. Expand
Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.
TLDR
This, the largest study to date of low-molecular-weight heparin use in pregnancy, confirms previous reports that it is a safe and effective alternative to unfractionated Heparin for obstetric thromboprophylaxis in high-risk women. Expand
Low‐Molecular‐Weight Heparin During Pregnancy and Delivery: Preliminary Experience With 41 Pregnancies
TLDR
This preliminary series, the largest reported to date, demonstrates the relative safety and efficacy of low-molecular-weight heparin therapy in pregnancy and delivery. Expand
Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy.
TLDR
It is concluded that LHN-1 at these doses does not cross the placenta during the second trimester of pregnancy to suggest that LHn-1 may be a safe alternative to heparin in the management of the thromboembolic complications during pregnancy. Expand
Heparin-induced thrombocytopenia is rare in pregnancy.
TLDR
Hemparin-induced thrombocytopenia is extremely rare in pregnant women and low-molecular-weight heparin is expensive but is associated with less frequent occurrences of hepar in the nonpregnant population. Expand
Low-molecular-weight heparin in pregnancy: peripartum bleeding complications
TLDR
Bleeding complications, including PPH and transfusion, in patients treated with LMWH during pregnancy were not increased when compared to normal controls matched for delivery route. Expand
...
1
2
3
4
5
...